ArcherDX Growth, Revenue, Number of Employees and Funding
Estimated Revenue & Financials
- ArcherDX's estimated revenue is currently $33.3M per year.
- ArcherDX received $35.0M in venture funding in March 2018.
- ArcherDX's estimated revenue per employee is $144891
- ArcherDX's total funding is $95M.
- ArcherDX has 230 Employees.
- ArcherDX grew their employee count by 64% last year.
- ArcherDX currently has 43 job openings.
|Matt Franklin||Chief Business Officer|
|Steven Daniel||Senior Director, Applied Sciences and Business Development|
|Doug Wendel||Senior Director|
|Mike Gomez||Director/Head of Quality|
|Todd Druley||Chief Medical Officer|
|Blake Alexander||Sales Director|
|Richard Sjogren||Vice President Operations|
|Abel Licon||Director of Software Research and Development|
|Aaron Berlin||Vice President of Bioinformatics and Commerical Software|
|Joshua Stahl||Chief Scientific Officer and GM|
What Is ArcherDX?
ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Mile High Labs||$26.2M||181||596%||$100M|
|Front Range Bio...||$7.3M||50||67%|
For example, Archer Immunoverse B Cell Receptor (BCR) was launched by ArcherDX, Inc in 2017 to examine human B cell repertoire.
BOULDER, Colo., May 15, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...
BOULDER, Colo., March 5, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough ...
|2018-03-21||$35.0M||A||Boulder Ventures, Ltd.||Article|
|2019-01-31||Baby Genes, Inc||Article|